Want to see AU:BDX full AI Analyst Report?
BDX Stock Chart & Stats
AU$0.10
>-AU$0.01(-2.06%)
At close: 4:00 PM EST
AU$0.10
>-AU$0.01(-2.06%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.16
Previous CloseN/A
Volume98.04K
Average Volume (3M)421.90K
Market Cap
AU$24.70M
Enterprise ValueAU$46.53M
Total Cash (Recent Filing)AU$3.33M
Total Debt (Recent Filing)AU$3.78M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding368,683,300
10 Day Avg. Volume534,308
30 Day Avg. Volume421,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.64
Price to Sales (P/S)1047.06
P/FCF Ratio-3.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology Diagnostics PipelineBCAL's focused business model targeting blood-based early cancer detection, especially breast cancer, is a durable strategic position. Specialization aligns with persistent clinical need and screening expansion, concentrating R&D and regulatory efforts toward a single, high-impact market niche.
Manageable Leverage And Equity BaseA low debt-to-equity ratio and a c.62.8% equity ratio provide structural financing flexibility. Manageable leverage reduces near-term refinancing pressure and supports the company's ability to raise R&D or clinical validation funding without acute solvency risk, aiding multi‑month program continuity.
Lean Operating FootprintA very small headcount implies a low fixed-cost base and operational flexibility, which can extend runway and focus capital on core R&D and validation activities. For diagnostic developers, lean operations can preserve cash while advancing clinical milestones.
Bears Say
Severe Revenue CollapseA c.99% revenue decline signals a structural loss of commercial traction or ended revenue source. Persistently collapsed top line undermines the business model, constrains reinvestment in trials and regulatory pathways, and raises the bar for demonstrating sustainable commercial adoption.
Negative Operating And Free Cash FlowConsistent negative operating cash flow and declining free cash flow indicate the company cannot self-fund development. Persistent cash burn increases reliance on external funding, elevates dilution and execution risk, and limits ability to complete clinical validation and commercial rollout.
Deep Losses And Negative ReturnsVery large negative margins and ROE reflect structural unprofitability. Such entrenched losses impair investor confidence, complicate capital raises, and suggest operational inefficiencies or an immature product-commercialisation pathway needing material improvement to reach sustainable profitability.
BCAL Diagnostics Limited News
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$24.70M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 27 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 368,683,300 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BCAL Diagnostics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.01%
Trailing 12-Months
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Technical Analysis
Healius Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―